文献速递冠心病

IL-1β与心肌梗死患者早亡风险的相关性

Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2020-08-27

该研究在1398例接受直接PCI的急性ST段抬高型心肌梗死患者中,评估入院时IL-1β水平与全因死亡的关系及其与hs-CRP的交互作用。结果显示,入院IL-1β与90天全因死亡独立相关,最高三分位组90天和1年死亡风险及心血管死亡、MACE风险均显著升高,且不依赖于hs-CRP水平。

要点

  • 入院IL-1β每升高1个标准差,90天全因死亡风险增加47%。
  • IL-1β最高三分位组90天全因死亡风险为最低组的2.78倍。
  • IL-1β与死亡风险的关联不依赖于hs-CRP水平。

核心结论

  • 急性心肌梗死患者入院时IL-1β水平与死亡和复发性MACE风险独立相关。

研究设计与样本

  • 前瞻性队列研究,纳入1398例接受直接PCI的急性ST段抬高型心肌梗死患者。
  • 采用多因素Cox比例回归分析90天和1年全因死亡、心血管死亡及MACE的风险比。

主要发现

  • 入院IL-1β每升高1个标准差,90天全因死亡校正风险比1.47(95%CI 1.16–1.87,p<0.002)。
  • IL-1β最高三分位组90天全因死亡校正风险比2.78(95%CI 1.61–4.79,p=0.0002),1年为1.93(95%CI 1.21–3.06,p=0.005)。
  • 最高三分位组90天心血管死亡校正风险比2.42(95%CI 1.36–4.28,p=0.002),MACE为2.29(95%CI 1.31–4.01,p=0.004)。
  • 最高三分位组1年心血管死亡校正风险比2.32(95%CI 1.36–3.97,p=0.002),MACE为2.35(95%CI 1.39–3.96,p=0.001)。
  • 上述关联与hs-CRP浓度无关。

临床怎么用

  • 对急性ST段抬高型心肌梗死直接PCI患者,入院IL-1β水平可能有助于识别早亡高危人群。
  • IL-1β的预后价值独立于hs-CRP,提示可考虑联合评估炎症通路风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhibition of the interleukin (IL)-1β innate immunity pathway is associated with anti-inflammatory effects and a reduced risk of recurrent cardiovascular events in stable patients with previous myocardial infarction (MI) and elevated high-sensitivity C-reactive protein (hs-CRP). OBJECTIVES: This study assessed the association between IL-1β level with all-cause mortality in patients with acute ST-segment elevation MI who underwent primary percutaneous coronary intervention and the interplay between IL-1β and hs-CRP concentrations on the risk of premature death. METHODS: IL-1β concentration was measured in 1,398 patients with ST-segment elevation MI who enrolled in a prospective cohort. Crude and hazard ratios for all-cause and cardiovascular mortality were analyzed at 90 days and 1 year using multivariate Cox proportional regression analysis. Major adverse cardiovascular events (MACEs) were analyzed. RESULTS: IL-1β concentration measured at admission was associated with all-cause mortality at 90 days (adjusted hazard ratio [adjHR]: 1.47 per 1 SD increase; 95% confidence interval [CI]: 1.16 to 1.87; p < 0.002). The relation was nonlinear, and the highest tertile of IL-1β was associated with higher mortality rates at 90 days (adjHR: 2.78; 95% CI: 1.61 to 4.79; p = 0.0002) and at 1 year (adjHR: 1.93; 95% CI: 1.21 to 3.06; p = 0.005), regardless of the hs-CRP concentration. Significant relationships were equally observed when considering cardiovascular mortality and MACEs at 90 days (adjHR: 2.42; 95% CI: 1.36 to 4.28; p = 0.002, and adjHR: 2.29; 95% CI: 1.31 to 4.01; p = 0.004, respectively) and at 1 year (adjHR: 2.32; 95% CI: 1.36 to 3.97; p = 0.002, and adjHR: 2.35; 95% CI: 1.39 to 3.96; p = 0.001, respectively). CONCLUSIONS: IL-1β measured at admission in patients with acute MI was independently associated with the risk of mortality and recurrent MACEs.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Silvain J, Kerneis M, Zeitouni M, et al. Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction. J Am Coll Cardiol. 2020. PMID: 32861811. doi:10.1016/j.jacc.2020.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。